Brief: XBiotech Announces French National Agency Approval For Cancer Treatment Study
28/04/2022 14:44
April 28 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES FRENCH NATIONAL AGENCY (ANSM) APPROVAL
AND
NATIONAL CANCER INSTITUTE (INSA) FUNDING TO SUPPORT PHASE
I/II/III CLINICAL STUDY FOR NATRUNIX™ IN COMBINATION WITH
TRIFLURIDINE/TIPIRACIL (TASKIN) FOR TREATMENT OF METASTATIC
COLORECTAL CANCER
* XBIOTECH INC- FRENCH NATIONAL CANCER INSTITUTE (INCA) HAS
ALSO
AWARDED A GRANT TO FUND ALL CLINICAL COSTS FOR STUDY
Source text for Eikon: ID:nGNX536sfY
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke